Ignyta executives Jacob Chacko and Jonathan Lim are encouraged by their first stage clinical trial results, and several stock analysts share their optimism.

Ignyta executives Jacob Chacko and Jonathan Lim are encouraged by their first stage clinical trial results, and several stock analysts share their optimism. Photo by Melissa Jacobs.

— Few biotechs were untouched by the gloomy market conditions of the past year, and local drugmaker Ignyta Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129